Abstract
Background
Inherited loss of function mutations in SCN5A have been linked to overlapping syndromes including cardiac conduction disease and Brugada syndrome (BrS). The mechanisms responsible for the development of one without the other are poorly understood.
Methods
Direct sequencing was performed in a family with cardiac conduction disease. Wild-type (WT) and mutant channels were expressed in TSA201 cells for electrophysiological study. Green fluorescent protein (GFP)-fused WT or mutant genes were used to assess channel trafficking.
Results
A novel SCN5A mutation, P1008S, was identified in all family members displaying 1st degree atrioventricular block, but not in unaffected family members nor in 430 reference alleles. Peak P1008S current was 11.77% of WT (p<0.001). Confocal microscopy showed that WT channels tagged with GFP were localized on the cell surface, whereas GFP-tagged P1008S channels remained trapped in intracellular organelles. Trafficking could be rescued by incubation at room temperature, but not by incubation with mexiletine (300µM) at 37°C. We also identified a novel polymorphism (D601E) in CACNB2b that slowed inactivation of L-type calcium current (ICa), significantly increased total charge. Using the Luo-Rudy action potential model, we show that the reduction in INa can cause loss of the right ventricular epicardial action potential (AP) dome in the absence but not in the presence of the slowed inactivation of ICa. Slowed conduction was present in both cases.
Conclusions
Our results suggest genetic variations leading to a loss-of-function in INa coupled with a gain of function in ICa may underlie the development of cardiac conduction disease without BrS.
Keywords: Conduction Disease, Sodium Channel, Calcium Channel, Protein Trafficking
INTRODUCTION
Mutations in SCN5A, encoding the α-subunit of the human cardiac sodium channel (hNav1.5), have been reported to cause overlapping syndromes including Brugada syndrome (BrS)1, LQT3 form of the long-QT syndrome2, cardiac conduction disease (CCD, also referred to as Lev-Lenègre disease)3, congenital sick sinus syndrome (SSS)4, and/or atrial fibrillation5, that can manifest individually or together.6–9
Cardiac conduction disease is characterized by an age-related impairment of conduction of the cardiac impulse across the atrioventricular node (AVN) and/or His-Purkinje system, leading to complete atrioventricular (AV) block, but without BrS-like ST-segment elevation.3 These patients may present with syncope or sudden death, necessitating implantation of a pacemaker or. Right or left bundle branch block (R/LBBB) and broadening of the PR interval, QRS-complex, and QT interval are commonly observed. SCN5A mutations have been linked to cardiac conduction disease, allowing for genotype-phenotype correlation, yet a clear mechanistic understanding and approach to therapy is lacking.
BrS has previously been associated with mutations in seven different genes including SCN5A (Nav1.5, BrS1)1, GPD1L (BrS2)10, CACNA1C (Cav1.2, BrS3)11, CACNB2b (Cavβ2b, BrS4)11, SCN1B (Navβ1, BrS5)12, KCNE3 (MiRP2; BrS6)13 and SCN3B (Navβ3, BrS7) 14 that when expressed lead to a loss of function of either sodium (INa) or L-type calcium (ICa) channel current or to a gain of function of transient outward current (Ito). Experimental studies have demonstrated that inhibition of either INa or ICa or a combination of the two inward currents can induce a BrS phenotype.15, 16
Whereas loss of function mutations in SCN5A often result in both BrS and some level of cardiac conduction disease, in some cases the latter is manifest without BrS.17–19 The mechanisms underlying the manifestation of cardiac conduction disease without BrS in cases of SCN5A loss of function mutations have largely eluded investigators thus far.
Herfst and colleagues showed that a trafficking defect may underlie SCN5A mutation-related loss of function associated with conduction defects20, but unlike BrS and LQT3, no study to our knowledge has identified a means to rescue SCN5A mutation-induced trafficking defects responsible for conduction problems. The present study identifies a novel missense mutation in SCN5A in a family with 1st degree AV block and demonstrates that loss of function is secondary to a trafficking defect that is amenable to rescue by exposure to low temperatures. Moreover, we have identified a second variation involving CACNB2b, which encodes the β subunit of the L-type calcium channel. This polymorphism, D601E, is shown to slow inactivation of ICa leading to a gain of function. Our data suggest that the dual genetic variation in inward current genes, causing a loss of function in INa coupled with a gain of function in ICa, underlies the development of cardiac conduction disease without BrS.
METHODS
Clinical Subjects
The study was approved by the Regional Institutional Review Board. All members of the immediate family underwent clinical and genetic studies after obtaining informed consent. The proband underwent Holter monitoring as well as an exercise stress test. P-wave duration, PR-interval, QT-interval, rate-corrected QT-interval and QRS-duration were measured from 12-lead electrocardiograms (ECG)s.
Mutation Analysis
Genomic DNA was extracted from peripheral blood leukocytes using a commercial kit (Gentra System, Puregene, Valencia, CA, USA). All exons and intron borders of SCN5A (Nav1.5), KCNE1 (MinK), KCNE2 (MiRP1), KCNE3 (MiRP2), KCNQ1 (KvLQT1), KCNH2 (hERG), KCNA4 (Kv1.4), KCND3 (Kv4.3), KCNIP2 (KChIP2), CACNA1C (Cav1.2), CACNB2b (Cavβ2b), and CACNA2D1 (Cavα2δ1), IRX5, DDP10 genes were amplified and directly sequenced from both directions with the use of an ABI PRISM 3100-Avant Automatic DNA sequencer (Applied Biosystems, Foster City, CA, USA). To determine the prevalence of the nucleotide variations in the same ethnic population, genomic DNA from 430 ethnically-matched healthy reference alleles was used as control. The following SCN5A and CACNB2b primers were used for screening of family members:
SCN5A | |
Exon 17- Sense | 5’-GTCAAGCGGACCACCTGG-3’ |
Exon 17- Antisense | 5’-CACACACACGGGCTCTGG-3’ |
CACNB2b | |
Exon 13b- Sense | 5’-GACTCTGCCTACGTAGAGC-3’ |
Exon 13b- Antisense | 5’-CACATATGATTGCAGTGTAGAC-3’ |
Site-Directed Mutagenesis, Transfection and Electrophysiology Study
The ion channel variants were cloned by site-directed mutagenesis, expressed in TSA201 cells and studied using whole cell patch clamp techniques as detailed in the online supplement.
Localization of Sodium Channel
We assessed channel trafficking using Na+ channels tagged with GFP, as previously described.11 Confocal microscopy was used to localize the channels and identify trafficking defects. (See online supplement for details)
Mathematical Model
Propagated action potentials (APs) were simulated using the Luo-Rudy 2 model21, 22 to which an robust Ito was added.23 (See online supplement for details)
Statistical Analysis
Data are expressed as Mean ± SEM. Two-tailed Student's t-test or ANOVA coupled with Newman-Keuls test were used for statistical analysis, as appropriate (SigmaStat, Jandel Scientific Software, Richmond, CA, USA). Differences were considered statistically significant at a value of P<0.05.
RESULTS
Clinical Observations
Affected family members were identified on the basis of generalized conduction defects (Table 1). The pedigree is shown in Figure 1. In the fall of 2004, the proband (II-1), 47 years old very fit male, presented in the emergency room after passing out at work. His younger daughter (III-2) was symptomatic with a reported “racing heart” during or following vigorous exercise. The proband and his two daughters (13 and 15 years old) underwent Holter monitoring and a treadmill stress test. The proband showed a pronounced first-degree AV block and an incomplete right bundle branch block (IRBBB), which were more pronounced during and after the exercise stress test (II-1 in Figure 2A–C). A bifid T wave and slight QTc prolongation were also observed during the exercise stress test (Figure 2B). His PR-interval varied between 300 and 360 ms at rest. The presence of a generalized conduction defect was also reflected in the longer than normal P wave and QRS duration (Table 1). Procainamide challenge failed to induce a BrS-like ECG (data not shown). Moreover, raising the position of the right precordial leads 2 intercostal spaces failed to reveal a BrS-ECG phenotype also. An ICD was implanted in the proband because of the unexplained syncope and a family history of sudden cardiac death.
Table 1.
Patient | Age (year) |
Gender | Heart Rate (bpm) |
P Wave Duration (ms) |
PR interval (ms) |
QRS Duration (ms) |
QT interval (ms) |
QTc interval (ms) |
---|---|---|---|---|---|---|---|---|
II-1 | 47 | Male | 60 | 130 | 300–360 | 105 | 400 | 400 |
II-1 After stress test |
60 | 160 | 280 | 120 | 440 | 440 | ||
III-1 | 15 | Female | 51 | 100 | 178 | 104 | 440 | 406 |
III-2 | 13 | Female | 50 | 120 | 224 | 85 | 412 | 376 |
The proband's sister (II-3) was 26 years old when she died of sudden cardiac arrest (21 years ago). The proband’s daughters, 15 and 13 years of age, displayed sinus arrhythmia, bradycardia and PR intervals of 178 and 224 ms, which are prolonged for their age24 (III-1 and 2; Figures 2D and 2E). One of the daughters had a mild form of epilepsy (III-2). The proband’s brother, mother and two nieces displayed a normal ECG.
Molecular Genetics
Polymerase chain reaction (PCR)-based sequencing analysis revealed a double peak in the sequence of exon 17 of SCN5A (C to T transition at nucleotide 3022), predicting substitution of proline by serine at codon 1008 (P1008S) in all family members displaying ECG conduction defects. The novel missense mutation is located in the intracellular linker between domains II and III of SCN5A. The nucleotide change was not observed in 430 reference alleles (215 healthy race-matched individuals). Because of the appearance of bifid T waves and slight QTc prolongation during the exercise stress test, the proband was also screened for variations in other genes mentioned above. A heterozygous T1803G transition in exon 13, that predicted a substitution of aspartate for glutamate at position 601 (D601E) of CACNB2b, was present in 23% of ethnically matched controls. This polymorphism is located downstream of the β-subunit interaction domain segment. The polymorphism was detected in the proband (II-1) and one of his daughters (III-1).
Electrophysiological Characteristics of the SCN5A-P1008S Mutation
SCN5A-P1008S mutant and wild type (WT) sodium channels were co-expressed with SCN1B in TSA201 cells to assess the effects of the mutation on sodium channel function. The I–V relationships shown in Figure 3C demonstrate a major loss of function with peak INa density of P1008S reduced to 11.77 % of WT. Steady-state inactivation was measured by varying the conditioning pulse between −140 mV and −60 mV to inactivate the channels followed by a test pulse to −20 mV (Figure 3A). Half-inactivation voltage (V1/2) and the slope factor of P1008S were not significantly different (Figure 3D). Recovery from inactivation evaluated using a standard double paired-pulse protocol showed that P1008S channels recover more slowly at very brief interpulse intervals (<20 ms) (Figure 3B and 3E).
To evaluate whether the loss of function caused by the P1008S mutation was due in part to a trafficking defect, we studied WT and P1008S channels tagged with fusion green fluorescent protein (GFP). XYZ scans of WT channels on the confocal microscope revealed both a central and peripheral pattern of staining, suggesting localization of the channel in the cell membrane as well as intracellular organelles (Figure 4A). In contrast, P1008S channel fluorescence was limited to intracellular organelles (Figure 4B), suggesting that channels were trapped in the endoplasmic reticulum and/or Golgi complex.
Previous studies have reported that trafficking of defective channels can be rescued by a variety of methods including incubation at low temperature and addition of pharmacological agents to the culture media25. Recent reports showed the effect of mexiletine, a Class I antiarrhythmic agent, to rescue trafficking-defective channels26. We evaluated the effect of both room temperature (RT), 22°C and mexiletine 300 µM. Incubation of the P1008S transfected cells with 300 µM mexiletine for 48 hours did not rescue the trafficking defective channels (Figure 4C). However, incubation of the P1008S mutant channels at RT for 48 hours re-established both central and peripheral staining, suggesting restoration of normal trafficking of the channels to the cell membrane (Figure 4D). The peripheral:total fluorescence ratio was similar for WT and P1008S incubated at RT (0.572±0.036 and 0.545±0.030, n=8 for each), but much smaller for P1008S and P1008S incubated with Mexiletine (0.247±0.037 and 0.341±0.058, P<0.05 compared with WT, n=8 for each).
In another series of experiments, we examined the effect of incubation at RT or with mexiletine on functional expression of INa. Figure 5 shows the effect of incubation of cells transfected with P1008S SCN5A at RT in 48 hrs or incubation with 300 µM mexiletine in 48 hrs. Incubation with 300 µM mexiletine at 37°C failed to rescue expression of P1008S mutant channels, whereas incubation at RT for 24–48 hrs restored robust inward currents, consistent with the confocal results demonstrating rescue of the trafficking deficient channels.
Electrophysiological Characteristics of the CACNB2b-D601E Polymorphism
To determine the contribution of calcium polymorphism to the clinical phenotype, we expressed the WT and mutated CACNB2b constructs in TSA201 cells with CACNA1c and CACNA2D1 and performed patch-clamp experiments (Figure 6A). The current density-voltage (I–V) relationship between WT and D601E channels was compared. A set of depolarizing pulses applied in 10-mV increments from a holding potential of −90 mV elicited robust ICa currents (Figure 6B). At 0 mV, the D601E variation in CACNB2b caused a slowing of inactivation: the time constant of the slow component of decay of ICa (τs) increased from 134.5 ± 11.0 in WT (n=9) to 168.8 ± 13.6 ms in D601E channels (n=7; P<0.01). The time constant of the fast component was not significantly altered (τf = 24.8 ± 2.1 ms for WT, n=9; τf = 24.0 ± 1.5 ms for D601E, n=7; P>0.05). This was accompanied by an increase in ICa density, which was statistically significant 50 and 300 ms into the pulse. (Figure 6C). The total charge carried by ICa, estimated as the area under the current trace recorded at 0 mV, increased by 144.3% (from 21.0±5.4 nC to 51.3±1.0 nC; n=9 for WT; n=7 for D601E; P<0.05).
Simulation Results
To assess the influence of the P1008S mutation in SCN5A alone and in combination with the D601E polymorphism in CACNB2b on the shape of the cardiac AP we simulated propagated right ventricular APs in a 1 cm cable. Figure 7 shows simulated APs under steady-state conditions (9th and 10th cycles) at BCL of 1000 msec. Maximal conductance of Ito was set to 2.2 mS/pF to simulate a right ventricular epicardial AP with a prominent spike-and-dome morphology (Figure 7A). When maximal conductance of fast INa was reduced to 35% of WT model to simulate the SCN5A defect, phase 0 overshoot decreased from +11.4 mV to −8.7 mV, conduction velocity slowed from 61 to 40 cm/sec (66% of WT) and the dome of the right ventricular epicardial action potential was lost (Figure 7B), consistent with the cellular changes associated with the development of Brugada syndrome.18 A decrease of the rate of voltage-dependent inactivation of ICa,L to 85% of WT, simulating the change produced by the D601E polymorphism in CACNB2b (Figure 7C), resulted in restoration of the dome of the simulated right ventricular epicardial AP, indicating that this gain of function of ICa can prevent loss of the AP dome and thus prevent the development of the substrate for Brugada syndrome.
DISCUSSION
Clinical Correlation
We report a novel heterozygous missense mutation in SCN5A (P1008S) associated with a mild conduction defect in a family with a history of sudden cardiac death. The mutation is shown to cause loss of proper transport and reduced functional expression of SCN5A, capable of being rescued by exposure to low temperatures. ECG manifestations of impaired conduction in affected patients included prolonged P wave, QRS duration and PR intervals as well as incomplete RBBB, sinus arrhythmias and bradycardia, all likely due to loss of sodium channel function.
Numerous studies have identified mutations in SCN5A.3 Impaired atrioventricular conduction is the most common conduction problem identified, usually as an autosomal dominant trait.
Electrophysiology
Most mutations associated with cardiac conduction disease are functional, exhibiting complex biophysical properties predicted to reduce channel availability, such as altered voltage-dependence of activation, more rapid fast inactivation or closed-state inactivation, or enhanced slow inactivation.27, 28 Tan and colleagues described an SCN5A mutation related to cardiac conduction disease, displaying changes in inactivation kinetics, although whole-cell Na+ current density remained unchanged.27 A loss of function mutation due to impaired protein trafficking has previously been associated with cardiac conduction disease, although a means of rescue was not identified in that study.20
In our study, the most striking feature of the P1008S channel was the severe reduction in INa amplitude. This loss of function is due to impaired trafficking since confocal microscopy revealed that P1008S channels fail to reach the plasma membrane. Patients with this mutation would be expected to have significantly reduced channel expression and consequently a reduced INa, which would be expected to reduce depolarizing current and excitability and thus account for the observed phenotype.29
Another possible contributor to the manifestation of the phenotype is the development of structural changes, as suggested by a recent SCN5A+/− mouse model which recapitulates the cardiac conduction disease phenotype. SCN5A+/− mice displayed progressive impairment of atrial and ventricular conduction associated with myocardial rearrangements and fibrosis. These conduction and structural abnormalities become more accentuated with advancing age.3, 30 It is noteworthy that in our P1008S family, the degree of conduction impairment was much more pronounced in the older member of the family (father). Association between degenerative abnormalities of the specialized conduction system and SCN5A loss of function has been demonstrated by Bezzina and co-workers in a case of compound heterozygosity.31
Loss of function mutations are often associated with BrS, although a number of previous studies have reported alleles exhibiting loss-of-function that are associated with cardiac conduction disease, without any manifestation of BrS.20, 27 The factors that determine the predominance of one phenotype over another are currently not well understood. The well-known clinical factors that may affect phenotypic expression include sex, age, and body temperature.19;32, 33 Genetic modifiers involve compound mutations34, spliced variant of SCN5A35, and a combination of polymorphisms.36 The disease penetrance also relate to humoral regulation, participation of auxiliary subunits, chaperone proteins, anchoring proteins and transcriptional factors.37
It is well known that the BrS phenotype is 8 to 10 times more prevalent in males versus females38, but sex-related difference among cardiac conduction disease patients is unknown. In one reported family manifesting both BrS and cardiac conduction disease, the phenotype appeared to be divided along gender lines. Four of 4 patients with BrS were males, whereas 6 of 7 progressive cardiac conduction disease patients were female.39 The presence of a more prominent Ito-mediated notch in the epicardium of males is thought to predispose males to the development of the Brugada phenotype, whereas a smaller epicardial notch in females protects them from BrS, but relegates them to development of cardiac conduction disease under conditions in which inward currents are compromised.40 A less dramatic outward shift in the balance of current active during the early phase of the action potential is thought to underlie the milder BrS phenotype in females.
In the present study, both male and female patients displayed the cardiac conduction disease phenotype, but none displayed the BrS phenotype, even when the right precordial leads were raised two intercostal spaces.33 The presence of a gain of function variation in CACNB2b leading to an increase in ICa likely underlies this unique phenotype. An increase in ICa mediated by administration of β adrenergic agonists or type 3 phosphodiesterase inhibitors such as cilostazol have been shown to suppress the BrS phenotype in both clinical and experimental studies. Augmentation of ICa prevents loss of action potential dome or restores the dome, thus preventing the development of ST segment elevation, phase 2 reentry and polymorphic ventricular tachycardia.41 This mechanism may be responsible for the manifestation of cardiac conduction disease without BrS in the proband (II-1) who displayed the SCN5A mutation as well as CACNB2b polymorphism. The presence of a milder form of cardiac conduction disease without manifestations of BrS in his two daughters is likely due to their young age and female gender, as discussed above. The presence of the CACNB2b polymorphism in one daughter (III-1) may have contributed to less severe conduction defect. The appearance of bifid T waves and QTc prolongation in the proband during exercise is consistent with a greater gain of function of ICa expected to be carried by the calcium channel polymorphism due to increased levels of circulating catecholamines during exercise (Figure 2B). Both daughters, one carrying the CACNB2b polymorphism and the other not, are likely protected from BrS by virtue of their female gender and young age.
Trafficking and Rescue
It is not clear why the P1008S mutation leads to the failure of the channels to reach the plasma membrane, and why this trafficking defect could be rescued by incubation of the transfected cells at room temperature, but not with mexiletine. Trafficking defects are thought to involve misfolding or improper assembly of the protein structure, leading to its retention in the endoplasmic reticulum and degradation without transport to the Golgi complex by the "quality control" system, in which lectin-like endoplasmic reticulum chaperones play a key role.42 Substitution of proline with serine has significant implications with respect to protein folding, and therefore, trafficking abnormalities and degradation. Specifically, insertion of a proline residue in place of the serine is likely to cause a sharp bend in the amino acid chain. Tertiary post-translational processing may be affected and thereby alter trafficking to the cell membrane.
The restoration of trafficking of mutant proteins is an experimental and therapeutic goal in protein trafficking-deficient inherited diseases, where the concept of chemical or pharmacological chaperones has emerged. Exposure to low temperature is thought to improve channel biogenesis by stabilizing the channel protein in a configuration that facilitates proper trafficking and may thus be effective in rescuing mutations that are not influenced by pharmacological agents.
Finally, using the Luo and Rudy cardiac action potential (AP) model,21 we demonstrate that the reduction in INa can cause loss of the right ventricular epicardial AP dome in the absence but not in the presence of the slowed inactivation of ICa. Slowed conduction was present in both cases.
Limitations and Conclusion
Our results suggest that genetic variations leading to a loss of function in INa coupled with a gain of function in ICa may underlie the development of cardiac conduction disease without Brugada syndrome. However, the small number of affected individuals in this family precludes us from reaching a definitive conclusion.
Supplementary Material
ACKNOWLEDGEMENTS
The authors are grateful to Judy Hefferon and Robert J. Goodrow, Jr. for technical assistance and Susan Bartkowiak for maintaining our genetic database.
Financial Support: This work was supported by the National Institutes of Health grant HL47678 (CA) and New York State and Florida Grand Lodges of Free and Accepted Masons.
Reference List
- 1.Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, et al. Genetic basis and molecular mechanisms for idiopathic ventricular fibrillation. Nature. 1998;392:293–296. doi: 10.1038/32675. [DOI] [PubMed] [Google Scholar]
- 2.Abriel H, Cabo C, Wehrens XH, Rivolta I, Motoike HK, Memmi M, Napolitano C, et al. Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na+ channel. Circ Res. 2001;88:740–745. doi: 10.1161/hh0701.089668. [DOI] [PubMed] [Google Scholar]
- 3.Schott JJ, Alshinawi C, Kyndt F, Probst V, Hoorntje TM, Hulsbeek M, Wilde AA, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet. 1999;23:20–21. doi: 10.1038/12618. [DOI] [PubMed] [Google Scholar]
- 4.Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, Rhodes TH, et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A) J Clin Invest. 2003;112:1019–1028. doi: 10.1172/JCI18062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, Horton SC, et al. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. JAMA. 2005;293:447–454. doi: 10.1001/jama.293.4.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bezzina C, Veldkamp MW, van Den Berg MP, Postma AV, Rook MB, Viersma JW, Van Langen IM, et al. A single Na+ channel mutation causing both long-QT and Brugada syndromes. Circ Res. 1999;85:1206–1213. doi: 10.1161/01.res.85.12.1206. [DOI] [PubMed] [Google Scholar]
- 7.Veldkamp MW, Wilders R, Baartscheer A, Zegers JG, Bezzina CR, Wilde AA. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res. 2003;92:976–983. doi: 10.1161/01.RES.0000069689.09869.A8. [DOI] [PubMed] [Google Scholar]
- 8.Grant AO, Carboni MP, Neplioueva V, Starmer CF, Memmi M, Napolitano C, Priori SG. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest. 2002;110:1201–1209. doi: 10.1172/JCI15570. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, et al. The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. J Clin Invest. 2008;118:2219–2229. doi: 10.1172/JCI34057. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Van Norstrand DW, Valdivia CR, Tester DJ, Ueda K, London B, Makielski JC, Ackerman MJ. Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome. Circulation. 2007;116:2253–2259. doi: 10.1161/CIRCULATIONAHA.107.704627. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff A, et al. Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115:442–449. doi: 10.1161/CIRCULATIONAHA.106.668392. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, Demolombe S, et al. Sodium channel b1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest. 2008;118:2260–2268. doi: 10.1172/JCI33891. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Delpón E, Cordeiro JM, Núñez L, Thomsen PEB, Guerchicoff A, Pollevick GD, Wu Y, et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol. 2008;1:209–218. doi: 10.1161/CIRCEP.107.748103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A, Pfeiffer R, et al. A mutation in the b3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet. 2009;2:270–278. doi: 10.1161/CIRCGENETICS.108.829192. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST segment elevation. Circulation. 1999;100:1660–1666. doi: 10.1161/01.cir.100.15.1660. [DOI] [PubMed] [Google Scholar]
- 16.Fish JM, Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm. 2004;1:210–217. doi: 10.1016/j.hrthm.2004.03.061. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Smits JP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Remme CA, Haverkamp W, et al. Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients. J Am Coll Cardiol. 2002;40:350–356. doi: 10.1016/s0735-1097(02)01962-9. [DOI] [PubMed] [Google Scholar]
- 18.Antzelevitch C. Brugada syndrome. PACE. 2006;29:1130–1159. doi: 10.1111/j.1540-8159.2006.00507.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Remme CA, Wilde AA, Bezzina CR. Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. Trends Cardiovasc Med. 2008;18:78–87. doi: 10.1016/j.tcm.2008.01.002. [DOI] [PubMed] [Google Scholar]
- 20.Herfst LJ, Potet F, Bezzina CR, Groenewegen WA, Le MH, Hoorntje TM, Demolombe S, et al. Na+ channel mutation leading to loss of function and non-progressive cardiac conduction defects. J Mol Cell Cardiol. 2003;35:549–557. doi: 10.1016/s0022-2828(03)00078-6. [DOI] [PubMed] [Google Scholar]
- 21.Luo CH, Rudy Y. A dynamic model of the cardiac ventricular action potential. I. Simulations of ionic currents and concentration changes. Circ Res. 1994;74:1071–1096. doi: 10.1161/01.res.74.6.1071. [DOI] [PubMed] [Google Scholar]
- 22.Zeng J, Laurita KR, Rosenbaum DS, Rudy Y. Two components of the delayed rectifier K+ current in ventricular myocytes of the guinea pig type. Theoretical formulation and their role in repolarization. Circ Res. 1995;77:140–152. doi: 10.1161/01.res.77.1.140. [DOI] [PubMed] [Google Scholar]
- 23.Dumaine R, Towbin JA, Brugada P, Vatta M, Nesterenko DV, Nesterenko VV, Brugada J, et al. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. Circ Res. 1999;85:803–809. doi: 10.1161/01.res.85.9.803. [DOI] [PubMed] [Google Scholar]
- 24.Brown L, Clark BJ, Morrow C. Clinical Handbook of Pediatrics. 3 ed. New York, NY: Lippincott Williams & Wilkins; 2003. [Google Scholar]
- 25.Robertson GA, January CT. HERG trafficking and pharmacological rescue of LQTS-2 mutant channels. Handb Exp Pharmacol. 2006:349–355. doi: 10.1007/3-540-29715-4_14. [DOI] [PubMed] [Google Scholar]
- 26.Tan BH, Valdivia CR, Rok BA, Ye B, Ruwaldt KM, Tester DJ, Ackerman MJ, et al. Common human SCN5A polymorphisms have altered electrophysiology when expressed in Q1077 splice variants. Heart Rhythm. 2005;2:741–747. doi: 10.1016/j.hrthm.2005.04.021. [DOI] [PubMed] [Google Scholar]
- 27.Tan HL, Bink-Boelkens MT, Bezzina CR, Viswanathan PC, Beaufort-Krol GC, van Tintelen PJ, van Den Berg MP, et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature. 2001;409:1043–1047. doi: 10.1038/35059090. [DOI] [PubMed] [Google Scholar]
- 28.Wang DW, Viswanathan PC, Balser JR, George AL, Jr, Benson DW. Clinical, genetic, and biophysical characterization of SCN5A mutations associated with atrioventricular conduction block. Circulation. 2002;105:341–346. doi: 10.1161/hc0302.102592. [DOI] [PubMed] [Google Scholar]
- 29.Shaw RM, Rudy Y. Electrophysiologic effects of acute myocardial ischemia: a theoretical study of altered cell excitability and action potential duration. Cardiovasc Res. 1997;35:256–272. doi: 10.1016/s0008-6363(97)00093-x. [DOI] [PubMed] [Google Scholar]
- 30.Royer A, van Veen TA, Le BS, Marionneau C, Griol-Charhbili V, Leoni AL, Steenman M, et al. Mouse model of SCN5A-linked hereditary Lenegre's disease: age-related conduction slowing and myocardial fibrosis. Circulation. 2005;111:1738–1746. doi: 10.1161/01.CIR.0000160853.19867.61. [DOI] [PubMed] [Google Scholar]
- 31.Bezzina CR, Rook MB, Groenewegen WA, Herfst LJ, van der Wal AC, Lam J, Jongsma HJ, et al. Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system. Circ Res. 2003;92:159–168. doi: 10.1161/01.res.0000052672.97759.36. [DOI] [PubMed] [Google Scholar]
- 32.Shimizu W, Matsuo K, Kokubo Y, Satomi K, Kurita T, Noda T, Nagaya N, et al. Sex hormone and gender difference--role of testosterone on male predominance in Brugada syndrome. J Cardiovasc Electrophysiol. 2007;18:415–421. doi: 10.1111/j.1540-8167.2006.00743.x. [DOI] [PubMed] [Google Scholar]
- 33.Yokokawa M, Noda T, Okamura H, Satomi K, Suyama K, Kurita T, Aihara N, et al. Comparison of long-term follow-up of electrocardiographic features in Brugada syndrome between the SCN5A-positive probands and the SCN5A-negative probands. Am J Cardiol. 2007;100:649–655. doi: 10.1016/j.amjcard.2007.03.078. [DOI] [PubMed] [Google Scholar]
- 34.Cordeiro JM, Barajas-Martinez H, Hong K, Burashnikov E, Pfeiffer R, Orsino AM, Wu YS, et al. Compound heterozygous mutations P336L and I1660V in the human cardiac sodium channel associated with the Brugada syndrome. Circulation. 2006;114:2026–2033. doi: 10.1161/CIRCULATIONAHA.106.627489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Tan BH, Valdivia CR, Song C, Makielski JC. Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletine. Am J Physiol Heart Circ Physiol. 2006;291:H1822–H1828. doi: 10.1152/ajpheart.00101.2006. [DOI] [PubMed] [Google Scholar]
- 36.Hu D, Viskin S, Oliva A, Carrier T, Cordeiro JM, Barajas-Martinez H, Wu Y, et al. Novel mutation in the SCN5A gene associated with arrhythmic storm development during acute myocardial infarction. Heart Rhythm. 2007;4:1072–1080. doi: 10.1016/j.hrthm.2007.03.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Viswanathan PC, Balser JR. Molecular basis of isolated cardiac conduction disease. Handb Exp Pharmacol. 2006:331–347. doi: 10.1007/3-540-29715-4_13. [DOI] [PubMed] [Google Scholar]
- 38.Brugada R, Brugada J, Antzelevitch C, Kirsch GE, Potenza D, Towbin JA, Brugada P. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation. 2000;101:510–515. doi: 10.1161/01.cir.101.5.510. [DOI] [PubMed] [Google Scholar]
- 39.Kyndt F, Probst V, Potet F, Demolombe S, Chevallier JC, Baro I, Moisan JP, et al. Novel SCN5A mutation leading either to isolated cardiac conduction defect or Brugada syndrome in a large French family. Circulation. 2001;104:3081–3086. doi: 10.1161/hc5001.100834. [DOI] [PubMed] [Google Scholar]
- 40.Fish JM, Antzelevitch C. Cellular and ionic basis for the sex-related difference in the manifestation of the Brugada syndrome and progressive conduction disease phenotypes. J Electrocardiol. 2003;36:173–179. doi: 10.1016/j.jelectrocard.2003.09.054. [DOI] [PubMed] [Google Scholar]
- 41.Antzelevitch C, Fish JM. Therapy for the Brugada syndrome. Handb Exp Pharmacol. 2006:305–330. doi: 10.1007/3-540-29715-4_12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Zhou Z, Gong Q, Epstein ML, January CT. HERG channel dysfunction in human long QT syndrome. Intracellular transport and functional defects. J Biol Chem. 1998;273:21061–21066. doi: 10.1074/jbc.273.33.21061. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.